Inicio › Cáncer (todos los tipos) › Pensilvania
Ensayos clínicos de Cáncer (todos los tipos) en Pensilvania
100 estudios sobre Cáncer (todos los tipos) buscan participantes en Pensilvania.
Ciudades en Pensilvania
- Philadelphia57 estudios
- Pittsburgh42 estudios
- York7 estudios
- Allentown7 estudios
- Harrisburg4 estudios
- Hazleton3 estudios
- Reading3 estudios
Texto oficial del estudio (inglés)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Alliance Cancer Specialists - Media, Media
- Guthrie Medical Group, Sayre
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 13 nov 2026 · NCT05920356Childhood Cancer Predisposition Study (CCPS)
- Children's Hospital of Philadelphia, Philadelphia
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT04511806RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Pennsylvania, Philadelphia
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 10 nov 2026 · NCT07002034Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Saint Luke's Cancer Center - Allentown, Allentown
- Saint Luke's University Hospital-Bethlehem Campus, Bethlehem
- y 21 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06580314Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Allegheny Health Network, Pittsburgh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07195591Pan Tumor Rollover Study
- Lancaster General Health, Lancaster
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT03899155Facial Expression Awareness Training to Understand and Recognize Emotions
- Children's Hospital of Philadelphia, Philadelphia
Reclutando
Edades de 6 a 13 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07923370Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Lehigh Valley Health Network, Allentown
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT04198766A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Allegheny General Hospital (AGH)-Allegheny Singer Research Institute, Pittsburgh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06901531A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- University of Pennsylvania, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06150157Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township
- IRMC Cancer Center, Indiana
- y 6 más
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07059884A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Alliance Cancer Specialists, PC, Horsham
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06119581A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
- UPMC Cancer Centers, Pittsburgh
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06311578Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
- Thomas Jefferson University - Clinical Research Institute, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- y 1 más
ReclutandoFase 2/3
Todas las edades · Todos los sexos · Actualizado el 2 nov 2026 · NCT03435796Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
- Fox Chase Cancer Center, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06959706A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 4021), Philadelphia
ReclutandoFase 1/2
1 Month – 17 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT07630974Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Children's Hospital of Philadelphia, Philadelphia
ReclutandoFase 2
Edades de 1 a 26 · Todos los sexos · Actualizado el 28 oct 2026 · NCT07680439Collection of Tissue Samples for Cancer Research
- University of Pittsburgh Medical Center, Pittsburgh
ReclutandoEstudio observacional
2 Months · Todos los sexos · Actualizado el 27 oct 2026 · NCT00900198Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- Children's Hospital of Philadelphia, Philadelphia
ReclutandoFase 2
Edades de 2 a 99 · Todos los sexos · Actualizado el 21 oct 2026 · NCT05783323Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100), Philadelphia
- UPMC Hillman Cancer Center ( Site 0101), Pittsburgh
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 oct 2026 · NCT07405164Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- UPMC Hillman Cancer Center, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT06162221Galleri® in the Medicare Population.
- Geisinger Bloomsburg Hospital - Bloomsburg, Bloomsburg
- FCCC - East Norriton, East Norriton
- FCCC - Buckingham, Furlong
- y 7 más
ReclutandoSe aceptan voluntarios sanos
Edades de 50 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT05673018A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
- University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT07725796A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT05123482A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275407, Philadelphia
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 oct 2026 · NCT07023289FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 oct 2026 · NCT05919264CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT03328078A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 3021), Philadelphia
ReclutandoFase 1/2
1 Month – 17 Years · Todos los sexos · Actualizado el 6 oct 2026 · NCT06941272Autoimmunity After Checkpoint Blockade
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04119713Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
- Allegheny General Hospital, Pittsburgh
ReclutandoEstudio observacional
Edades de 20 a 89 · Mujeres · Actualizado el 30 sept 2026 · NCT07023887A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- Allegheny General Hospital, Pittsburgh
Reclutando
Edades de 20 a 89 · Mujeres · Actualizado el 30 sept 2026 · NCT07698314A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07192471EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- AHN Allegheny General Hospital, Pittsburgh
Reclutando
Edades de 20 a 89 · Mujeres · Actualizado el 28 sept 2026 · NCT07704476A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07277270First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
- GSK Investigational Site, Philadelphia
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07438782A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- St. Lukes University Hospital /ID# 280204, Bethlehem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07365241TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lehigh Valley Hospital - Cedar Crest, Allentown
- Lehigh Valley Hospital- Muhlenberg, Bethlehem
- Pocono Medical Center, East Stroudsburg
- y 2 más
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- Geisinger Medical Center-Cancer Center Hazleton, Hazleton
- y 4 más
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06756607A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Fox Chase Cancer Center, Philadelphia
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06634589De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.